DOP2022000053A - Degradadores bifuncionales de brd9 y sus métodos de uso - Google Patents

Degradadores bifuncionales de brd9 y sus métodos de uso

Info

Publication number
DOP2022000053A
DOP2022000053A DO2022000053A DO2022000053A DOP2022000053A DO P2022000053 A DOP2022000053 A DO P2022000053A DO 2022000053 A DO2022000053 A DO 2022000053A DO 2022000053 A DO2022000053 A DO 2022000053A DO P2022000053 A DOP2022000053 A DO P2022000053A
Authority
DO
Dominican Republic
Prior art keywords
brd9
methods
degraders
bifunctional
bifunctional degraders
Prior art date
Application number
DO2022000053A
Other languages
English (en)
Inventor
Sendzik Martin
LORBER Julien
Chen Xin
GOUDE Marie-Line
Martin Harrington Edmund
John Hollingworth Gregory
Vulpetti Anna
Zoller Thomas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DOP2022000053A publication Critical patent/DOP2022000053A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La divulgación proporciona compuestos bifuncionales para BRD9 de Fórmula (A), o una de sus sales, hidratos, solvatos, profármacos, estereoisómeros o tautómeros farmacéuticamente aceptables, su preparación, composiciones farmacéuticas que los comprenden, y su uso en el tratamiento de enfermedades y trastornos mediados por una proteína con bromodominio, tal como proteína con bromodominio 9 (BRD9).
DO2022000053A 2019-09-16 2022-03-10 Degradadores bifuncionales de brd9 y sus métodos de uso DOP2022000053A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900863P 2019-09-16 2019-09-16
US201962900860P 2019-09-16 2019-09-16
US201962900865P 2019-09-16 2019-09-16
US201962900869P 2019-09-16 2019-09-16
PCT/US2020/050768 WO2021055295A1 (en) 2019-09-16 2020-09-14 Brd9 bifunctional degraders and their methods of use

Publications (1)

Publication Number Publication Date
DOP2022000053A true DOP2022000053A (es) 2023-01-31

Family

ID=72915891

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000053A DOP2022000053A (es) 2019-09-16 2022-03-10 Degradadores bifuncionales de brd9 y sus métodos de uso

Country Status (19)

Country Link
US (1) US20220315578A1 (es)
EP (1) EP4041724A1 (es)
JP (1) JP2022547952A (es)
KR (1) KR20220063192A (es)
CN (1) CN114641473A (es)
AU (1) AU2020349451B2 (es)
BR (1) BR112022003514A2 (es)
CA (1) CA3153529A1 (es)
CO (1) CO2022002842A2 (es)
CR (1) CR20220105A (es)
DO (1) DOP2022000053A (es)
EC (1) ECSP22018571A (es)
IL (1) IL290677A (es)
JO (1) JOP20220069A1 (es)
MX (1) MX2022003102A (es)
PE (1) PE20221417A1 (es)
TW (1) TW202123942A (es)
UY (1) UY38880A (es)
WO (1) WO2021055295A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746135A4 (en) 2018-01-30 2022-03-09 Foghorn Therapeutics Inc. METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2023512040A (ja) * 2020-01-29 2023-03-23 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
CN115806547A (zh) * 2021-09-09 2023-03-17 C4医药公司 选择的用于brd9的靶向降解的化合物
CN118339151A (zh) * 2021-12-15 2024-07-12 西藏海思科制药有限公司 一种抑制或降解brd9的化合物及其组合物和药学上的应用
WO2023200800A1 (en) * 2022-04-11 2023-10-19 Foghorn Therapeutics Inc. Methods of treating androgen receptor-independent prostate cancer
WO2024163609A1 (en) * 2023-02-01 2024-08-08 Foghorn Therapeutics Inc. Compositions for treating cancer
CN117229202B (zh) * 2023-11-15 2024-01-26 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA3025806C (en) * 2016-06-23 2023-04-04 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
MX2019009046A (es) * 2017-01-31 2019-10-30 Arvinas Operations Inc Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.
EP3774808A1 (en) * 2018-03-26 2021-02-17 Novartis AG 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
CN111936498B (zh) * 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
WO2020051235A1 (en) * 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
EP3917517A4 (en) * 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF

Also Published As

Publication number Publication date
ECSP22018571A (es) 2022-04-29
WO2021055295A1 (en) 2021-03-25
BR112022003514A2 (pt) 2022-05-17
TW202123942A (zh) 2021-07-01
JP2022547952A (ja) 2022-11-16
JOP20220069A1 (ar) 2023-01-30
IL290677A (en) 2022-04-01
CN114641473A (zh) 2022-06-17
AU2020349451A1 (en) 2022-04-21
AU2020349451B2 (en) 2024-02-01
KR20220063192A (ko) 2022-05-17
CR20220105A (es) 2022-06-13
PE20221417A1 (es) 2022-09-20
MX2022003102A (es) 2022-04-06
UY38880A (es) 2021-04-30
EP4041724A1 (en) 2022-08-17
US20220315578A1 (en) 2022-10-06
CO2022002842A2 (es) 2022-04-19
CA3153529A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
CO2022002842A2 (es) Degradadores bifuncionales de brd9 y sus métodos de uso
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CL2022001111A1 (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
CL2017002022A1 (es) Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
NI201600049A (es) Inhibidores de kras g12c
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
ECSP088296A (es) Compuestos terapéuticos
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
CR20160527A (es) Derivados de carboxamida
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CL2019000727A1 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.
CL2017001602A1 (es) Derivados de fumagilol.
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
CU20160170A7 (es) Derivados de carboxamida